Linda Gonzalez
Medical · McAllen, TXNPI 1063530681
Payments from drug & device makers
Across 102 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$646
- Novo Nordisk$425
- Abbott$213
- Amgen$119
- Phadia US Inc.$73
- AbbVie$71
- plus $382 from 11 others
What the payments were for
- Food & beverage$1,930100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $646 |
| Novo Nordisk | 18 | $425 |
| Abbott | 10 | $213 |
| Amgen | 6 | $119 |
| Phadia US Inc. | 4 | $73 |
| AbbVie | 4 | $71 |
| AstraZeneca | 3 | $63 |
| Cumberland Pharmaceuticals, Inc. | 4 | $53 |
| Genentech USA, Inc. | 6 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Evofem Biosciences, Inc. | 2 | $30 |
| GSK | 1 | $25 |
| Organon | 2 | $21 |
| Pfizer | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,930 in reported general payments places this provider in the 65th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $80,767 |
| MounjaroTirzepatide | 32 | $34,607 |
| RybelsusSemaglutide | 11 | $28,067 |
| XareltoRivaroxaban | 15 | $21,837 |
| TrulicityDulaglutide | 19 | $19,126 |
| TradjentaLinagliptin | 17 | $17,134 |
| EliquisApixaban | 13 | $16,079 |
| LinzessLinaclotide | 11 | $9,333 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,952 |
| Atorvastatin Calcium | 185 | $1,851 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,653 |
| NovologInsulin Aspart | 11 | $1,557 |
| Gabapentin | 87 | $1,546 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 15 | $1,486 |
| SynthroidLevothyroxine Sodium | 19 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $425 | $110,39291 claims |
| Lilly USA, LLCMounjaro, Trulicity | $646 | $53,73351 claims |
| PfizerEliquis | $20 | $16,07913 claims |
| AbbVieLinzess, Synthroid | $71 | $10,63730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,490 medical providers in Texas.
Other medical in McAllen
- Jason HenslerMcAllen$66K
- Edgar GarciaMcAllen$17K
- Claudia MaldonadoMcAllen$15K
- Rolando VelazquezMcAllen$13K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.